Opportunity timeline
In plain English
Los Alamos National Laboratory is offering licenses for a bacterial lipid nanodiscs platform that uses native bacterial membrane extracts to create stable, nanoscale particles for research. The technology can support vaccine, drug, diagnostic and biodefense research without handling live high-risk pathogens. It is at TRL 3, has a U.S. patent pending (LA-UR-26-24920), and is available through exclusive or non-exclusive licensing agreements; this is not a request for development services.
About this opportunity
The Bacterial Lipid Nanodiscs Platform developed by Los Alamos National Laboratory provides a new way to study entire bacterial membranes in a controlled, nanoscale format derived directly from native lipid extracts. Researchers gain access to membrane components that typically remain difficult to isolate, stabilize or analyze, enabling more accurate evaluation of immunogenic lipids and membrane?associated targets. The platform offers a safer alternative to handling live high?risk pathogens while preserving the biological context that drives meaningful insights for vaccine design and antimicrobial discovery such as therapeutic antibodies to conserved lipids on bacterial membranes. How it…
Time remaining
Closes Dec 16, 2026
Related Opportunities

Illumina DRAGEN Tier 3 Throughput License and v4 Server

Emergent Drug Panel-Version 2 (EDP-V2) Kit

Medicinal Chemistry Support Program for Therapeutic Development (MCSP)

Medicinal Chemistry Support Program for Therapeutic Development (MCSP)

Health Advisory Committees Research and Support
Bid details are gathered and summarized automatically. Please verify details at the original source.
Ref No.
BS-F93F62

